Real-World Comparison of Anti-CD20 Therapies in a German Neuroimmunology Cohort

262 patients with neuroimmunological diseases were observed over a median period of 36 months while treated with ocrelizumab, ofatumumab, or rituximab. The dataset, authored by Jakob Stögbauer and shared under CC-BY-4.0, includes quarterly monitoring of relapses, infection rates, immunoglobulin concentrations, and cellular immunity changes via flow cytometry. Results show low annual relapse rates and differences in infection frequency and hypogammaglobulinemia occurrence between therapies.

Use Cases

• Compare relapse rates between ocrelizumab, ofatumumab, and rituximab treatments based on longitudinal patient data.
• Analyze infection risk differences associated with specific anti-CD20 therapies based on monitored infection rates.
• Investigate the development of hypogammaglobulinemia over time in patients on different B-cell depleting agents.
• Model changes in lymphocyte subpopulations and T-cell function in response to treatment based on flow cytometry data.
• Inform individualized treatment strategies for neuroimmunological diseases based on efficacy and safety profiles.

Strengths

• 262 patient records provide a substantial cohort for analysis.
• Median observation period of 36 months offers longitudinal data on treatment outcomes.
• Multidimensional immune profiling includes flow cytometry data for cellular subsets and T-cell function.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single German cohort, which may limit generalizability to other populations.

Provenance

Source

figshare

Collection Method

Clinical observation and laboratory analysis of patients treated at an unspecified institution.

Time Range

Observation period includes a median of 36 months per patient.

Freshness

Last updated 2026-05-12 04:19:07; freshness should be verified.

Geography

Data originates from a German patient cohort.